Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Immuron (IMRN) EBIT Margin (2016 - 2024)

Immuron's quarterly EBIT Margin came in at 63.56% in Q4 2024, up 2220.0% year-on-year from 2.74% in Q1 2024, and up 25.88% quarter-over-quarter from 85.76% in Q4 2023.

Immuron has reported EBIT Margin for 9 years, with the latest figure at 63.56% in Q4 2024.

  • For the quarter ending Q4 2024, EBIT Margin rose 2220.0% year-over-year to 63.56%; the trailing twelve-month figure through Dec 2024 stood at 63.56% (up 72344.0% YoY), and the FY2025 full-year result was 73.34%, up 4498.0% from the prior year.
  • EBIT Margin for Q4 2024 stood at 63.56%, up from 85.76% in the prior quarter.
  • The five-year high for EBIT Margin was 2.18% in Q4 2022, with the low at 1494.83% in Q2 2023.
  • Average EBIT Margin over 5 years is 470.17%, with a median of 236.12% recorded in 2020.
  • Year-over-year, EBIT Margin tumbled 40173 bps in 2021 and soared 78604 bps in 2022.
  • Tracing IMRN's EBIT Margin over 5 years: stood at 386.48% in 2020, then slumped by 104 bps to 788.22% in 2021, then soared by 100 bps to 2.18% in 2022, then slumped by 3834 bps to 85.76% in 2023, then gained by 26 bps to 63.56% in 2024.
  • The last three EBIT Margin figures came in at 63.56% (Q4 2024), 85.76% (Q4 2023), and 1494.83% (Q2 2023), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBIT Margin (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - -
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn -6.43%
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - -
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn 38.10%
7 Evaxion A 62.56 Bn 62.54 Bn - -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn 17.83%
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn 23.02%
10 Immuron 1.27 Bn 1.27 Bn - -

Historic Data

Download Data 🔒
DateValue
Dec 31, 2024 -63.56%
Dec 31, 2023 -85.76%
Jun 30, 2023 -1,494.83%
Dec 31, 2022 -2.18%
Dec 31, 2021 -788.22%
Dec 31, 2020 -386.48%
Dec 31, 2019 -97.59%
Dec 31, 2018 -161.71%
Dec 31, 2017 535.49%
Dec 31, 2016 482.10%
Jun 30, 2016 502.15%